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Abstract
In a study aimed at correlating cytokine levels in synovial fluid with the pathology of rheumatoid arthritis (RA), tumour necrosis factor a, interleukin 113 and interferon y were immunoassayed in 27 patients with RA, 16 patients with other arthritides, 23 with osteoarthritis, 13 patients with trauma, and 18 patients at necropsy without inflammatory disease and not known to have had joint disease (median 27 hours after death). The results for interleukin 113 clearly show higher cytokine levels in patients with RA and other arthritides than in patients with osteoarthritis, trauma, or the patients at necropsy. Interferon y levels in patients with osteoarthritis and the patients at necropsy, however, were significantly greater than in patients with RA, and tumour necrosis factor a levels were also greater in the patients at necropsy compared with patients with RA. This study also correlated histomorphological patterns of synovitis and indicators of local inflammatory activity with synovial fluid cytokine levels, showing, for example, a positive association of interleukin 113 titre and a negative association of interferon y titre with ulcerogranulomatous synovitis (itself associated with RA). Taken together, these results extend and strengthen data suggesting a possible part played by increased synovial fluid levels of interleukin 113 in joint destruction in RA, but provide no evidence for increases in levels of tumour necrosis factor a or interferon y affecting the disease pathology. Several cytokines which function as immunological mediators of inflammation may also cause joint destruction in rheumatoid arthritis (RA). 1 2 Interleukin 1 stimulates the secretion of prostaglandin E2, platelet derived growth factor, and collagenase by fibroblasts and chondrocytes, and the proliferation offibroblasts and their production of fibronectin, type I collagen, and proteoglycans. Tumour necrosis factor a also stimulates fibroblast and chondrocyte production of prostaglandin E2 and collagenase, bone resorption, and fibroblast proliferation. Various other factors have also been implicated, such as interleukin 6, which stimulates the acute phase production of proteins such as C reactive protein, and enhances antibody production including rheumatoid factors,2 and interferon y which stimulates the expression of major histocompatibility complex class II molecules on synovial cells, implicated in triggering autoimmune T cells.
According to several papers, these cytokines are found in the synovial fluid of patients with RA, which supports their part in the immunopathology of RA. Several other cytokines, including the major T cell growth factor interleukin 2,3 are, however, not found in synovial fluid either by bioassay, immunoassay, or as mRNA. Moreover, whereas there seems to be a consensus on interleukin 1 and interleukin 6, several workers have reported low levels or the absence of interferon y16 and tumour necrosis factor a5 in synovial fluid from patients with RA, and deficient secretion of interferon y and tumour necrosis factor y by stimulated peripheral blood mononuclear cells.7 x One problem in interpreting the previous studies on the cytokine content in synovial fluid is the absence of normal control subjects which leaves open the possibility that findings in patients with RA may not necessarily be abnormal. Most studies have compared cytokine levels in patients with RA with those in patients with osteoarthritis or trauma, and conclusions on increased cytokine levels therefore are not necessarily relevant to normal joints. Where synovial fluid from non-arthritic subjects has been examined, levels of tumour necrosis factor a and interferon y higher than in patients with RA have sometimes been reported.5
As it is almost impossible to obtain synovial fluid from the joints of normal volunteers, this study determined interleukin 113, tumour necrosis factor a, and interferon y in synovial fluid from [14] [15] [16] [17] [18] Acute or chronic inflammatory activity was defined by grading the amount of granulocytes or fibrin, or both, or the number of lymphoplasmacellular elements respectively.
Of these parameters, in this study population, there was a significant (p<005) association between RA and acute but not chronic inflammatory activity, between RA and ulcerous synovitis, between osteoarthritis and serofibrous synovitis, and between RA and fibrotic changes (Kahle P, unpublished data).
IMMUNOASSAYS
Tumour necrosis factor a and interferon y were determined by radioimmunoassay kits purchased from Medgenix (Dusseldorf, Germany). Interleukin 113 was measured in an enzyme linked immunoassay (ELISA) using kits from Cistron Biotechnology (Pine Brook, NJ, USA). The tumour necrosis factor a, interferon y, and interleukin ,13 assays had sensitivities of 10 pg/ml, 1 U/ml, and 20 pg/ml respectively. The tumour necrosis factor a assay showed no cross reactivity with tumour necrosis factor 13, interleukin 1, interleukin 2 nor interferons; the interferon y assay did not react with up to 103 U/mI interferon 1B, and the interleukin 113 assay showed no cross-reactivity on interleukin 1ca, interleukin 2, tumour necrosis factor a, nor interferon y (manufacturers' data). Results obtained using these kits were transferred directly from the measuring device (y counter or ELISA reader) to a PC for data analysis using in house computer programs (Schaudt et al, in preparation).
STATISTICAL ANALYSIS
Student's t test was used for parametric analyses, whereas the Mann-Whitney U test was used for non-parametric analysis. contained more interferon y and tumour necrosis factor a than synovial fluid from patients with RA, but this did not reach significance. Table 2 shows that the interleukin 113 titre was significantly positively associated with the ulcerogranulomatous pattern of synovitis (ulcerous synovitis) compared with the serofibrous synovitis pattern (not associated with RA). Furthermore, there is also an association between the presence of transformed appearing cells in the synovial membrane and the interleukin 113 titre. In contrast, interferon y showed a negative association with ulcerous synovitis and a significant positive association with low activity serofibrous synovitis. Although the tumour necrosis factor a titre was low, it was also significantly increased in ulcerous compared with serofibrous synovitis.
Results
Of further interest were the significant positive associations between histologically defined grades ofacute and chronic inflammatory activity in synovial tissue biopsy samples and the amount of synovial fluid interleukin 113 ( RA' as well as in their serum.'" It is further implied that interleukin 113 titres are associated with joint pathology by the novel finding of a significant quantitative correlation between levels of interleukin 113 in synovial fluid and certain histomorphological patterns of synovitis (table 2) . Thus, for example, in independent analyses, ulcerogranulomatous synovitis was found to be significantly positively associated with RA,'0 and is here shown to be positively associated with the interleukin 113 titre. Grades of acute or chronic inflammation, as well as fibrotic status in synovial biopsy samples, have also been correlated with cytokine titres (table  3) . These data are consistent with a report that the level of interleukin 113 in serum samples correlates with clinical disease activity,'' but this had not previously been shown directly in the joint. In agreement with the supposition that synovial fluid from normal joints contains less or no interleukin 1I3, data presented here show that not only do synovial fluid samples from patients with trauma and osteoarthritis contain little interleukin ,13, but that synovial fluid from patients at necropsy has none. So far, there has been little possibility of measuring cytokine levels in normal joints, and our results with patients at necropsy reflect an attempt to find a group of control subjects without rheumatic disease. Where 'normal' joints have been examined previously, little interleukin 1 has been found.5
In contrast to results for interleukin 113, reports on the presence of interferon y and tumour necrosis factor a in synovial fluid from patients with rheumatoid arthritis have been contradictory. This may in part be due to the different immunoassays or even bioassays used to determine the cytokines. Several workers found little or no tumour necrosis factor a and interferon y in synovial fluid from patients with rheumatoid arthritis;' 12 others did succeed in showing their presence, albeit sometimes only in a fraction of patients with RA. 13 For example, in one study of 59 patients with RA, very high levels of tumour necrosis factor a were found in only one synovial fluid sample, high levels in two, detectable levels in a further 16 , and none in the remaining 40 either by bioassay or immunoassay. 14 In the studies where these two cytokines were found, it was difficult to judge whether their presence was pathological because normal controls were not included. Some workers have found large amounts of these cytokines in 'normal' control subjects and low levels or none in patients with RA,5 a result in agreement with the present data on synovial fluid from patients at necropsy and patients with RA. Other workers have found tumour necrosis factor a in synovial fluid from patrients with RA but only low levels in 'normal' synovial fluid (actually from patients with trauma).'5 Compared with the results on synovial fluid from patients at necropsy we also found low levels of tumour necrosis factor a in synovial fluid from patients with trauma, so these results may not be discrepant as seems at first sight.
The presence of relatively low levels of tumour necrosis factor a and interferon y in most synovial fluid samples from patients with RA may also be consistent with several reports of defects in the ability of RA lymphocytes to secrete these cytokines after stimulation in vitro,7 8 16 though even this is not always observed. 17 Tumour necrosis factor cx is not generally present in serum samples from normal donors, but tumour necrosis factor was shown in serum samples from patients with RA." Tetta et al used a variant bioassay for tumour necrosis factor which did not distinguish between tumour necrosis factor ai and tumour necrosis factor r), and may also have been affected by other factors. 8 Unlike interferon y, however, tumour necrosis factor ai is secreted by synovial tissue itself,'5 9 so secretion by peripheral blood mononuclear cells may not reflect synovial fluid levels.
Thus, taken together with the present results, a consensus from published work allows the conclusion that in synovial fluid from patients with RA, interleukin 1f3 is generally increased, interferon y is generally decreased, and tumour necrosis factor at is equivocal, with a few patients having increased tumour necrosis factor a but most decreased tumour necrosis factor a. This may reflect heterogeneity in the RA processes or disease stage, as well as different techniques for the measurement of >1 ng/ml of tumour necrosis factor a. In the light of these results, it could even be questioned whether RA could be viewed as associated with a deficiency in the production of the inflammatory cytokines tumour necrosis factor a and interferon y, rather than a dysregulated pathological increase. This would be consistent with the fact that several drugs used to treat RA are known to potentiate aspects of immune responsiveness by blocking prostaglandin E2 production or by enhancing cytokine secretion.20 Tumour necrosis factor a and interferony are generally thought of as substances involved in the upregulation of the immune response, but they may also participate in negative regulatory control, by direct growth inhibitory effects, or by immunoregulation. Thus, for example, tumour necrosis factor a (but not interferon y) has been shown to inhibit selectively clonal expansion of a subset of helper T cells.2' Cytokine networks within the rheumatoid joint are, however, clearly more complex than understood at present and other identified factors such as interleukin 822 are likely to play a part in the pathological process. Therefore, much more needs to be established before substitution treatments designed to correct cytokine defects acquire a convincing rationale. Nonetheless, a preliminary report on the treatment of RA with interferon y has illustrated the potential value of this approach.23
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